HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines

被引：30

作者：

Flis, Sylwia ^{[1
]}

Gnyszka, Agnieszka ^{[1
]}

Splawinski, Jacek ^{[1
]}

机构：

[1] Natl Med Inst, Dept Pharmacol, PL-00725 Warsaw, Poland

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2009年 / 387卷 / 02期

关键词：

HDACi; MS275; SBHA; Oxaliplatin; Colorectal cancer; Apoptosis; Synergism; HISTONE DEACETYLASE INHIBITORS; APOPTOSIS; DIFFERENTIATION; DEATH;

D O I：

10.1016/j.bbrc.2009.07.017

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Histone deacetylases (HDACs) play an important role in the epigenetic regulation of gene expression by catalyzing the removal of acetyl groups, stimulating chromatin condensation, and promoting transcriptional repression. Since aberrant epigenetic changes are a hallmark of cancer, HDACs appear a promising target for pharmacological inhibition. To test this we have addressed the hypothesis that histone deacetylase inhibitors (HDACi). MS275 and SBHA, potentiate inhibitory effects of classical anti-colorectal cancer cytostatic, oxaliplatin, on survival of colorectal cancer (CRC) cells in vitro. We are reporting here that HDACi shows potent synergistic interaction with oxaliplatin. The observed synergism between HDACi and oxaliplatin is most probably related to the augmented apoptotic signal and allowed for significant reduction of doses of anticancer agents used. (C) 2009 Elsevier Inc. All rights reserved.

引用

页码：336 / 341

页数：6

共 16 条

[1] Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy [J].

Carew, Jennifer S. ;

Giles, Francis J. ;

Nawrocki, Steffan T. .

CANCER LETTERS, 2008, 269 (01) :7-17

[2] ANALYSIS OF COMBINED DRUG EFFECTS - A NEW LOOK AT A VERY OLD PROBLEM [J].

CHOU, TC ;

TALALAY, P .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1983, 4 (11) :450-454

[3] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].

CHOU, TC ;

TALALAY, P .

ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55

[4] Acetylation of proteins as novel target for antitumor therapy: Review article [J].

Di Gennaro, E ;

Bruzzese, F ;

Caraglia, M ;

Abruzzese, A ;

Budillon, A .

AMINO ACIDS, 2004, 26 (04) :435-441

[5] Histone deacetylase inhibitors: Overview and perspectives [J].

Dokmanovic, Milos ;

Clarke, Cathy ;

Marks, Paul A. .

MOLECULAR CANCER RESEARCH, 2007, 5 (10) :981-989

[6] Histone deacetylase inhibitors and genomic instability [J].

Eot-Houllier, Gregory ;

Fulcrand, Geraldine ;

Magnaghi-Jaulin, Laura ;

Jaulin, Christian .

CANCER LETTERS, 2009, 274 (02) :169-176

[7] Enhancing the apoptotic and therapeutic effects of HDAC inhibitors [J].

Frew, Ailsa J. ;

Johnstone, Ricky W. ;

Bolden, Jessica E. .

CANCER LETTERS, 2009, 280 (02) :125-133

[8] Isobolographic analysis of interactions: An update on applications and utility [J].

Gessner, PK .

TOXICOLOGY, 1995, 105 (2-3) :161-179

[9]

Laurent A, 2005, CANCER RES, V65, P948

[10] Histone deacetylase inhibitors: Multifunctional anticancer agents [J].

Liu, Tao ;

Kuljaca, Selena ;

Tee, Andrew ;

Marshall, Glenn M. .

CANCER TREATMENT REVIEWS, 2006, 32 (03) :157-165

← 1 2 →